Date: March 15, 2003 Event: Eastern Psychological Association Conference Location: Baltimore, MD Emily Catherine Worsnopp A Comparison of Activity Levels in Wistar, Spontaneously Hypertensive, and Wistar-Kyoto Rats Date: March 14, 2003 Event: 2003 Annual Meeting of the Eastern Psychological Association Location: Baltimore, MD Christina Marie Del Valle An investigation of spatial learning in wistar-kyoto rats Date: March 14, 2003 Event: 2003 Annual Meeting of the Eastern Psychological Association Location: Baltimore, MD Matthew Aaron Oaks Glucose enhances memory formation for passive avoidance learning in day old chicks
A: In a 2023 Phase 2 trial, participants on the highest dose (12 mg) lost an average of 24.2% of their body weight over 48 weeks, and they had not yet reached a weight loss plateau
A 2015 animal study published in Clinical and Experimental Hypertension has found that berberine may also delay the onset of or reduce the risk of high blood pressure ( 17 )
Ipamorelin shows minimal effect No appetite stimulation: Unlike ghrelin itself, Ipamorelin does not significantly activate hunger pathways in published studies Published Research on Ipamorelin Study Model Key Finding Raun et al., 1998 (Eur J Endocrinol) Swine/Human Selective GH release without cortisol/prolactin elevation Johansen et al., 1999 Human (Phase I/II) Dose-response relationship with no significant adverse effects Bowers et al., 2004 Review Comparative analysis of GHRP selectivity profiles Head-to-Head Comparison Research Factor CJC-1295 Ipamorelin Receptor Target GHRH-R GHS-R1a (Ghrelin receptor) Signaling Pathway cAMP / PKA PLC / Calcium GH Release Pattern Amplifies natural pulsatile release Induces acute GH pulse Cortisol Impact Minimal Minimal Prolactin Impact Minimal Minimal Research Focus Sustained GH elevation models Selective/clean GH pulse models Typical Research Duration No DAC: 30min half-life / DAC: days ~2 hour half-life Why Researchers Study Them Together The combination of a GHRH analog (CJC-1295) with a GHRP (Ipamorelin) is well-documented in published literature
His pioneering work on incretin hormones established the scientific foundation for GLP-1based therapies in type 2 diabetes
Russo A, Tellone E, Barreca D, et al
